Roche announced that the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody has received approval from the U.S. FDA. When a patient has low HER2 expression, this antibody can be used to identify them and assist assess whether Enhertu is a good targeted treatment choice for them.
Eli Lilly and Company declared that the expanded use of Verzenio (abemaciclib) in conjunction with endocrine therapy (ET) has received approval from the U.S. FDA. Adjuvant treatment for adult patients with hormone receptor-positive (HR+), HER2-negative, node-positive early breast cancer (EBC) who are at high risk of recurrence is now permitted with this approval.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5626
Published Date: Feb 12, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing research and development in cancer diagnostic technologies and the popularity of HER2 testing for breast cancer screening are the major factors driving the growth of the HER2 testing market.
The market size of HER2 testing is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.
The major players in the market are Thermo Fisher Scientific, Roche, Empire Genomics Inc., Abnova Corporation, Eli Lilly and Company, Oxford Gene Technology IP Limited, Genetech, Genemed Technologies Inc., PERKINELMER Inc., and others.
The breast cancer segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.